
a TLR4 agonist in combination with an allergen. In another embodiment, the present disclosure provides compositions comprising an adjuvant, such as GLA of formula I or Ia or Ib, or DSLP of Formula I or Ia, or a TLR4 agonist in combination with an allergen for treating food allergies or seasonal allergies.


[0006] In any of the embodiments herein, the adjuvant is GLA of formula (Ia):



or a pharmaceutically acceptable salt thereof, where: R1, R3, R5 and R6 are C11-C20 alkyl; and R2 and R4 are C12-C20 alkyl; in a more specific embodiment, the GLA has the formula (Ia) set forth above wherein R1, R3, R5 and R6 are C11-14 alkyl; and R2 and R4 are C12-15 alkyl. In a further more specific embodiment, the GLA has the formula (Ia) set forth above wherein R1, R3, R5 and R6 are C11 alkyl, or undecyl; and R2 and R4 are C13 alkyl, or tridecyl. In yet a further specific embodiment, the GLA has the formula (Ia) set forth above wherein R1, R3, R5 and R6 are undecyl and R2 and R4 are tridecyl.

[0007] Exemplary amounts of GLA for dosing humans, including adult humans, include 0.1-10 μg, or 0.1-20 μg, or 1-20 μg or 0.2-5 μg, or 0.5-2.5 μg, or 0.5-8 μg or 0.5-15 μg per dose.

[0007a] In one aspect of the present disclosure, there is provided a use of a composition comprising (a) GLA of the formula (Ia):




or a pharmaceutically acceptable salt thereof, where:

R^1, R^3, R^5 and R^6 are C_{11}-C_{20} alkyl; and

R^2 and R^4 are C_{12}-C_{20} alkyl; and

(b) a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for treating a mammal who suffers from an allergic condition, wherein one dose of a composition comprising GLA is to be administered daily for at least four weeks.

[0007b] In a further aspect of the present disclosure, there is provided a use of a composition comprising (a) GLA of the formula (Ib):



or a pharmaceutically acceptable salt thereof;

wherein: L1, L2, L3, L4, L5 and L6 are the same or different and are independently selected from O , NH , and (CH2) ; L7, L8, L9 and L10 are the same or different, and at any occurrence may be either absent or C(=O) ; Y1 is an acid functional group; Y2 and Y3 are the same or different and are each independently selected from OH, SH, and an acid functional group; Y4 is OH or SH; R1, R3, R5 and R6 are the same or different and are each independently selected from the group of C8-C13 alkyl; and R2 and R4 are the same or different and are each independently selected from the group of C6-C11 alkyl; and


(b) a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for treating a mammal who suffers from an allergic condition, wherein one dose of a composition comprising GLA is to be administered daily for at least four weeks.

[0008] Non-parenteral administration can include delivery routes such as oral, sublingual, intranasal, intratracheal, intrapulmonary or mucosal delivery. Examples include administration via intranasal instillation, intratracheal instillation, intranasal inhalation or oral inhalation.

[0009] The present disclosure also provides methods and compositions for treating allergic conditions wherein the time period between doses of GLA, e.g. between maintenance doses, or between active treatment periods (between induction phases), is at least 1 month or longer. Thus, the disclosure provides a method of treating a mammal who

CLAIMS

1. Use of a composition comprising (a) GLA of the formula (Ia):



or a pharmaceutically acceptable salt thereof, where:

R^1, R^3, R^5 and R^6 are C_{11}-C_{20} alkyl; and

R^2 and R^4 are C_{12}-C_{20} alkyl; and

(b) a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for treating a mammal who suffers from an allergic condition, wherein one dose of a composition comprising GLA is to be administered daily for at least four weeks.

2. The use of claim 1 wherein R^1, R^3, R^5 and R^6 are undecyl and R^2 and R^4 are tridecyl.

3. The use of claim 1 wherein the allergic condition is not a seasonal allergic condition.

4. The use of claim 1 wherein the mammal suffers from a food allergy.

5. The use of any one of claims 1-4 wherein the composition is to be administered by oral, oral inhalation, sublingual, intranasal, intranasal inhalation, intrapulmonary, intratracheal instillation, or mucosal delivery.

6. The use of any one of claims 1-4 wherein the mammal is a human.

7. The use of claim 1 wherein the composition is to be administered via liquid formulation, aerosol, or nebulizer, optionally liquid or powder.

8. The use of any one of claims 1-4 wherein the amount of GLA is about 1-20 μg.

9. The use of any one of claims 1-4 wherein the composition further comprises one or more allergens.


10. The use of claim 9, wherein the one or more allergens is a food allergen.

11. The use of claim 10 wherein the food allergen is a milk allergen, an egg allergen, a peanut allergen, a fish allergen or a shellfish allergen.

12. The use of any one of claims 1-4 wherein the mammal is to be administered a second therapeutic agent.

13. The use of claim 1wherein the mammal has suffered one or more episodes of acute bronchial asthma.

14. Use of a composition comprising (a) GLA of the formula (Ib):



or a pharmaceutically acceptable salt thereof;

wherein: L1, L2, L3, L4, L5 and L6 are the same or different and are independently selected from O , NH , and (CH2) ; L7, L8, L9 and L10 are the same or different, and at any occurrence may be either absent or C(=O) ; Y1 is an acid functional group; Y2 and Y3 are the same or different and are each independently selected from OH, SH, and an acid

functional group; Y4 is OH or SH; R1, R3, R5 and R6 are the same or different and are each independently selected from the group of C8-C13 alkyl; and R2 and R4 are the same or different and are each independently selected from the group of C6-C11 alkyl; and

(b) a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for treating a mammal who suffers from an allergic condition, wherein one dose of a composition comprising GLA is to be administered daily for at least four weeks.